Journal of Cancer Research and Therapeutics

REVIEW ARTICLE
Year
: 2020  |  Volume : 16  |  Issue : 7  |  Page : 1555--1559

Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review


Beibei Yin1, Junjuan Xiao1, Junwei Li1, Xiaohong Liu2, Jun Wang1 
1 Department of Oncology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, Shandong Lung Cancer Institute, Jinan, China
2 Department of Pathology, The People's Liberation Army, No. 960 Hospital, Jinan, China

Correspondence Address:
Jun Wang
Department of Oncology, The First Affiliated Hospital of Shandong First Medical University; Shandong Lung Cancer Institute, Jinan
China

Immune checkpoint blockade with programmed cell death protein-1 (PD-1)/programmed cell death ligand-1 (PD-L1) inhibitors has been standard care for metastatic nonsmall cell lung cancer (NSCLC) and after progression using first-line platinum-containing chemotherapy. Although several management guidelines exist for immune checkpoint inhibitor-induced toxicities, uncommon, complicated, and life-threatening immune-related adverse events remain challenging for oncologists. In this report, we presented a male patient with NSCLC who received pembrolizumab during disease progression. He developed interstitial pembrolizumab-induced organizing pneumonia (OP). The patient received 9 months of anti-PD-1 pembrolizumab when he presented with dry cough and fatigue. The patient developed a solitary nodular lung lesion mimicking a newly occurred metastatic lesion in the lung without a significant circulating tumor marker increase. Sputum analysis was negative for acid-fast bacilli and fungi. A computed tomography-guided percutaneous lung biopsy was conducted and showed alveolar fibrous thickness and various lymphocyte infiltration. Immunotherapy-related OP was identified, and he subsequently responded well to corticosteroids. This case describes a clinical situation, where PD-1-induced OP is radiologically similar to NSCLC disease progression in the lungs. Oncologists should be aware of uncommon pulmonary PD-1/PD-L1 inhibitor toxicity. Lung biopsy may help to distinguish immune-related pneumonitis, lung infections, and progressive nodular lesions.


How to cite this article:
Yin B, Xiao J, Li J, Liu X, Wang J. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.J Can Res Ther 2020;16:1555-1559


How to cite this URL:
Yin B, Xiao J, Li J, Liu X, Wang J. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review. J Can Res Ther [serial online] 2020 [cited 2021 Mar 5 ];16:1555-1559
Available from: https://www.cancerjournal.net/article.asp?issn=0973-1482;year=2020;volume=16;issue=7;spage=1555;epage=1559;aulast=Yin;type=0